Zipwardinib在用大脑传播治疗具有攻击性的肺癌方面表现出了希望,但在一次小型试验中却造成了严重的副作用。 Zipalertinib showed promise in treating aggressive lung cancer with brain spread, but caused serious side effects in a small trial.

泰霍瘤学和Cullinan Therapeutics在ESMO大会2025上提交了2b期REZILIENT2试验的初步数据,显示研究中的EGFR抑制剂齐帕尔蒂尼布在16名EGFR外基因20插入或罕见突变和活跃大脑转移的NSCLC患者中,具有31. 3%的内反应率和68. 8%的疾病控制率. Taiho Oncology and Cullinan Therapeutics presented preliminary Phase 2b REZILIENT2 trial data at ESMO Congress 2025, showing zipalertinib, an investigational EGFR inhibitor, had a 31.3% intracranial response rate and 68.8% disease control rate in 16 NSCLC patients with EGFR exon 20 insertion or uncommon mutations and active brain metastases. 该药物每天剂量为100毫克,每天两次,在27.6%的病人中也显示出系统性反应,脑损伤的中位反应持续时间为8.1个月,系统反应时间为7.6个月。 The drug, given at 100 mg twice daily, also showed systemic responses in 27.6% of patients, with a median response duration of 8.1 months for brain lesions and 7.6 months systemically. 25%的人发生了三级或三级以上与治疗有关的不利事件,包括间歇性肺病,造成一人死亡。 Grade 3 or higher treatment-related adverse events occurred in 25%, including interstitial lung disease, which caused one death. 这些数据支持齐帕尔蒂尼布治疗中枢神经系统参与的难以治疗的NSCLC亚组的潜力,尽管它仍在研究中,未得到批准. The data support zipalertinib’s potential for treating a hard-to-treat NSCLC subgroup with CNS involvement, though it remains investigational and unapproved.